Table 2.
Time schedule for enrolment, intervention, and assessments.
| Study period | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Enrolment | Allocation | Post-allocation | Close out | |||||||
| Time point (month) | t −1 | t0 | t1 | t2 | t3 | t4 | t5 | t6 | …. t24 | |
| Enrolment: | ||||||||||
| Eligibility for screening | x | |||||||||
| Informed consent | x | |||||||||
| Allocation | x | |||||||||
| Interventions: | ||||||||||
| Optimized cancer screening | x | x | x | x | x | x | ||||
| Standard cancer screening | x | x | x | x | x | x | ||||
| Usual care | x | x | x | x | x | x | ||||
| Evaluations: | ||||||||||
| Proportion of women aged 40 to 65 having undergone a screening test in the last 3 years at 6 months after the intervention. | x | |||||||||
| Proportion of cytological tests among all screening tests performed |
x | |||||||||
| Proportion of HPV tests among all screening tests performed | x | |||||||||
| Proportion of abnormal test results (cytology, HPV) among all screening tests performed. | x | |||||||||
| Proportion of biopsies and conizations among abnormal screening test results at 12 months | x | |||||||||
| Proportion of high-grade lesions detected (second and third-grade cervical intraepithelial neoplasms including in situ carcinoma and cancers) among abnormal screening tests at 12 months | x | |||||||||
| Proportion of treatments performed (conization, laser, hysterectomy) among abnormal screening tests at 12 months | x | |||||||||
| Proportion of women having consulted a GP, a midwife or a gynecologist for a screening test | x | |||||||||
| Time lapse from dispatch of the invitation to the date of the screening test | x | |||||||||